Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body's own immune system to fight cancer. Unum's lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, is expected to enter Phase I clinical testing in the coming months to assess safety and efficacy. Unum is seeking partners interested in using the ACTR technology to arm proprietary tumor-specific antibodies with a T-cell to improve their therapeutic potential. The company is headquartered in Cambridge, MA.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/21/14 | $12,000,000 | Series A |
Atlas Venture | undisclosed |
| 06/11/15 | $65,000,000 | Series B |
Atlas Venture Brace Pharma Cowen Private Investments Jennison Associates New Leaf Venture Partners Novo A/S Sabby Management Sectoral Asset Management Wellington Management Company | undisclosed |
| 07/08/20 | $104,400,000 | Series A |
Acorn Bioventures Ally Bridge Group Atlas Venture BVF Partners Commodore Capital Fairmount Funds Management  Logos Capital OrbiMed Advisors Perceptive Advisors RTW Investments Samsara BioCapital Venrock Healthcare Partners | undisclosed |
